Neonatal lupus is a rare condition in newborns caused not by the baby’s own immune system, but by specific antibodies passed from mother to baby during pregnancy. These antibodies, called anti-Ro/SSA and anti-La/SSB, cross the placenta and can affect the baby’s skin, heart, liver, and blood cells. Most symptoms are temporary and resolve on their own within months, but one complication, congenital heart block, can be permanent.
Despite its name, neonatal lupus is not the same as systemic lupus erythematosus (SLE). A baby with neonatal lupus does not have lupus. Many mothers who carry these antibodies don’t have lupus either. They may have Sjögren’s syndrome, another autoimmune condition, or no diagnosed disease at all.
How Maternal Antibodies Cause the Condition
The immune system of a mother with certain autoimmune conditions produces anti-Ro/SSA and anti-La/SSB antibodies. These antibodies are small enough to cross the placenta, typically during the second trimester. Once in the baby’s circulation, they can bind to the baby’s tissues and trigger inflammation. The heart’s electrical conduction system is particularly vulnerable because these antibodies can damage the tissue that carries electrical signals between the upper and lower chambers of the heart.
The occurrence of congenital heart block is estimated at 1% to 2% in infants of mothers with SLE who carry these antibodies. That means the vast majority of at-risk pregnancies result in healthy babies with no complications. However, if a mother has already had one child affected by heart block, the recurrence risk in future pregnancies is historically around 18%.
The Skin Rash and Other Temporary Symptoms
The most recognizable sign of neonatal lupus is a distinctive skin rash. It appears at birth or within the first few months of life and looks like roundish rings with a discolored, often red border. The center of each ring is clear, showing normal skin tone. The rash most commonly appears on the baby’s scalp and face but can also develop on the trunk, arms, or legs. Sunlight or UV exposure from phototherapy (used to treat newborn jaundice) can sometimes trigger or worsen the rash.
Beyond the skin, neonatal lupus can temporarily affect the liver, causing mildly abnormal liver function, and the blood, leading to low counts of red blood cells, white blood cells, or platelets. These findings are typically mild and detected through routine blood work rather than visible symptoms.
All of these non-cardiac symptoms clear up once the maternal antibodies pass out of the baby’s body, usually by 6 to 9 months of age. No long-term treatment is needed for the rash, liver involvement, or blood count changes.
Congenital Heart Block
The most serious complication of neonatal lupus is congenital heart block, where the electrical signals that coordinate the heartbeat are partially or completely disrupted. In complete (third-degree) heart block, the upper and lower chambers of the heart beat independently of each other, causing a dangerously slow heart rate.
Unlike the rash and blood abnormalities, heart block caused by neonatal lupus is usually permanent. The damage to the heart’s conduction tissue occurs during fetal development, most often between 18 and 24 weeks of gestation, and the scarring does not reverse after the maternal antibodies clear.
Some babies with complete heart block need a pacemaker. The typical indicators for pacemaker placement include a heart rate below 55 beats per minute, signs of heart failure, or other cardiac abnormalities. The pacemaker is placed on the surface of the heart (epicardial) rather than through the blood vessels, given the baby’s small size. Many children with pacemakers go on to live active, normal lives, though the device requires lifelong monitoring and periodic replacement.
Prenatal Screening for At-Risk Pregnancies
If you test positive for anti-Ro/SSA or anti-La/SSB antibodies, your pregnancy will be monitored more closely for signs of fetal heart block. The American Heart Association recommends fetal echocardiograms (ultrasound of the baby’s heart) starting at 16 weeks of gestation, followed by weekly or biweekly scans until 28 weeks. If you’ve had a previously affected child, weekly surveillance from 16 to 28 weeks is advised.
Fewer than 20% of heart block cases are first detected after 26 weeks, so if no abnormalities have appeared by that point, the screening frequency can often be reduced. The goal of this monitoring is to catch early signs of heart rhythm problems when intervention might still be possible, such as incomplete heart block that hasn’t yet progressed to complete block.
Reducing the Risk in Future Pregnancies
For mothers who have already had a child with congenital heart block, hydroxychloroquine (a medication commonly used to manage lupus and other autoimmune conditions) has shown meaningful benefit in preventing recurrence. A study published in the Journal of the American College of Cardiology found that hydroxychloroquine reduced the recurrence rate of congenital heart block from the historical 18% to 7.4%, a reduction of more than 50%. The drug works by interfering with the inflammatory pathway that the maternal antibodies use to damage fetal heart tissue.
Hydroxychloroquine is generally started before or early in pregnancy and continued throughout. It is considered safe for use during pregnancy and is now recommended for secondary prevention in mothers with a prior affected child.
Long-Term Outlook for Affected Children
For babies whose only symptoms were rash, liver, or blood involvement, the prognosis is excellent. Once the maternal antibodies clear by 6 to 9 months, there are typically no lasting effects from those symptoms.
Children with neonatal lupus do not appear to have an increased risk of developing systemic lupus themselves as they grow up. A long-term follow-up study from a neonatal lupus registry tracked 49 affected children and 45 unaffected siblings. No child in either group developed SLE. However, six of the affected children did develop other autoimmune or inflammatory conditions during early childhood, including juvenile arthritis, thyroid disease, and psoriasis. All six of those children had mothers with active autoimmune disease. None of the unaffected siblings developed these conditions.
This pattern suggests that the risk for future autoimmune issues is tied more to having a mother with autoimmune disease than to having had neonatal lupus specifically. By adolescence and young adulthood, children who had neonatal lupus and their unaffected siblings showed no elevated risk for systemic rheumatic diseases. Still, periodic check-ups through childhood are reasonable, particularly before adolescence and especially if the mother has an active autoimmune condition.